Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 4 (2007), Issue 5 (May)

1. Cognitive decline in Alzheimer disease: Impact of spirituality, religiosity, and QOL.
   Neurology, 68(18): 1509-14. [Abstract] [Full-text]
2. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.
   Neurology, 68(18): 1501-8. [Abstract] [Full-text]
3. Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice.
   Behav Neurosci, 121(2): 340-4. [Abstract] [Full-text]
4. Donepezil: an update.
   Expert Opin Pharmacother, 8(7): 1011-23. [Abstract] [Full-text]
5. Differing profiles of face and scene discrimination deficits in semantic dementia and Alzheimer's disease.
   Neuropsychologia, 45(9): 2135-46. [Abstract] [Full-text]
6. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
   J Neurochem, 101(4): 1053-9. [Abstract] [Full-text]
7. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
   Arch Gerontol Geriatr, 45(1): 19-26. [Abstract] [Full-text]
8. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer's disease.
   J Nucl Med, 48(5): 704-11. [Abstract] [Full-text]
9. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.
   Ann Neurol, 61(5): 435-45. [Abstract] [Full-text]
10. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1.
    J Clin Invest, 117(5): 1230-9. [Abstract] [Full-text]
11. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.
    Ann Neurol, 61(5): 446-53. [Abstract] [Full-text]
12. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Science, 316(5825): 750-4. [Abstract] [Full-text]
13. Synthesis and binding studies of Alzheimer ligands on solid support.
    J Org Chem, 72(10): 3614-24. [Abstract] [Full-text]
14. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment.
    J Neuropathol Exp Neurol, 66(5): 389-98. [Abstract] [Full-text]
15. Alzheimer's disease drug discovery from herbs: neuroprotectivity from beta-amyloid (1-42) insult.
    J Altern Complement Med, 13(3): 333-40. [Abstract] [Full-text]
16. Identification and characterization of OGG1 mutations in patients with Alzheimer's disease.
    Nucleic Acids Res, 35(8): 2759-66. [Abstract] [Full-text]
17. Exercising restraint: clinical, legal and ethical considerations for the patient with Alzheimer's disease.
    Accid Emerg Nurs, 15(2): 94-100. [Abstract] [Full-text]
18. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Neurology, 68(19): 1603-6. [Abstract] [Full-text]
19. Predictors of progression from mild cognitive impairment to Alzheimer disease.
    Neurology, 68(19): 1596-602. [Abstract] [Full-text]
20. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Neurology, 68(19): 1588-95. [Abstract] [Full-text]
21. Relationship between neuronal loss and 'inflammatory plaques' in early onset Alzheimer's disease.
    Neuropathol Appl Neurobiol, 33(3): 328-33. [Abstract] [Full-text]
22. Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease.
    Neuropathol Appl Neurobiol, 33(3): 317-27. [Abstract] [Full-text]
23. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
    Expert Rev Neurother, 7(5): 473-85. [Abstract] [Full-text]
24. Stereological analysis of neuropil threads in the hippocampal formation: relationships with Alzheimer's disease neuronal pathology and cognition.
    Neuropathol Appl Neurobiol, 33(3): 334-43. [Abstract] [Full-text]
25. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Neuroimage, 36(2): 298-312. [Abstract] [Full-text]
26. Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.
    Arch Neurol, 64(5): 738-45. [Abstract] [Full-text]
27. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template.
    Biochemistry, 46(20): 6118-25. [Abstract] [Full-text]
28. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association.
    Genomics, 89(6): 655-65. [Abstract] [Full-text]
29. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts.
    Prog Neurobiol, 82(1): 11-32. [Abstract] [Full-text]
30. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein.
    J Neurosci, 27(20): 5394-404. [Abstract] [Full-text]
31. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Lancet Neurol, 6(6): 501-12. [Abstract] [Full-text]
32. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding.
    BMC Neurosci, 8: 29. [Abstract] [Full-text]
33. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.
    Neurology, 68(21): 1809-14. [Abstract] [Full-text]
34. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein.
    Biochem Biophys Res Commun, 358(2): 644-9. [Abstract] [Full-text]
35. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
    Neurology, 68(21): 1800-8. [Abstract] [Full-text]
36. The use of grid computing to drive data-intensive genetic research.
    Eur J Hum Genet, 15(6): 694-702. [Abstract] [Full-text]
37. Similarities in the thermodynamics and kinetics of aggregation of disease-related Abeta(1-40) peptides.
    Protein Sci, 16(6): 1214-22. [Abstract] [Full-text]
38. A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation.
    Biochem Biophys Res Commun, 358(3): 777-82. [Abstract] [Full-text]
39. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.
    Neurology, 68(22): 1902-8. [Abstract] [Full-text]
40. Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease.
    Neurology, 68(22): 1895-901. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.